Clarivate Plc (CLVT)
After hours:
| Previous Close | 6.85 |
| Open | 6.92 |
| Bid | 0.00 x 4000 |
| Ask | 0.00 x 4000 |
| Day's Range | 6.87 - 7.06 |
| 52 Week Range | 6.07 - 10.03 |
| Volume | |
| Avg. Volume | 4,355,596 |
| Market Cap | 4.71B |
| Beta (5Y Monthly) | 1.24 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -1.47 |
| Earnings Date | May 08, 2024 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 8.39 |
PR NewswireClarivate Introduces Epidemiology Intelligence™ for Precision Patient Population Analysis
Clarivate Plc (NYSE: CLVT), a leading global provider of transformative intelligence, today announced the launch of Epidemiology Intelligence™. The new solution combines rich insights from epidemiology, incidence and prevalence database solutions. It includes U.S. claims-based population insights to empower biopharma companies to accurately gauge market size and target patient demographics with ease.
- PR Newswire
Clarivate Enhances Cortellis CMC Intelligence with Post-Approval Module to Accelerate Regulatory Success
Clarivate Plc (NYSE:CLVT), a leading global provider of transformative intelligence, today announced the launch of the newly enhanced Cortellis CMC Intelligence™ solution, featuring a new post-approval variations module. The module for post-approval variations covers regulatory changes across multiple countries, offering meticulously curated requirements to streamline tracking. With this update, pharmaceutical, biotech, and generics companies can effortlessly navigate the regulatory process and
- PR Newswire
Clarivate Declares Dividend on Mandatory Convertible Preferred Shares
Clarivate Plc (NYSE: CLVT; CLVT PR A) ("Clarivate"), a leading global provider of transformative intelligence, today announced that its board of directors declared a quarterly dividend of $1.3125 per share on its 5.25% Series A Mandatory Convertible Preferred Shares (the "Preferred Shares"), payable in cash on June 3, 2024 to shareholders of record at the close of business on May 15, 2024.
